Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.

ABSTRACT: Gastro-esophageal adenocarcinomas (GEA) represent a severe global health burden and despite improvements in the multimodality treatment of these malignancies the prognosis of patients remains poor. HER2 overexpression/amplification has been the first predictive biomarker approved in clinical practice to guide patient selection for targeted treatment with trastuzumab in advanced gastric and gastro-esophageal junction cancers. More recently, immunotherapy has been approved for the treatment of GEA and PD-L1 expression is now a biomarker required for the administration of pembrolizumab in these diseases. Significant progress has been made in recent years in dissecting the genomic makeup of GEA in order to identify distinct molecular subtypes linked to distinct patterns of molecular alteration

SUBMITTER: Battaglin F 

PROVIDER: S-EPMC6042434 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature